Home › Funds › FARALLON CAPITAL MANAGEMENT, L.L.C. › CRNX
FARALLON CAPITAL MANAGEMENT, L.L.C. position in CRNX
CRINETICS PHARMACEUTICALS IN
FARALLON CAPITAL MANAGEMENT, L.L.C. reported holding 8,989,098 shares of CRNX (CRINETICS PHARMACEUTICALS IN) in its Q2 2026 13F filing — a position valued at US$336.4M, representing 1.56% of its reported portfolio and ranking #22 among its reported holdings. FARALLON CAPITAL MANAGEMENT, L.L.C. has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How FARALLON CAPITAL MANAGEMENT, L.L.C.'s CRNX position evolved
FARALLON CAPITAL MANAGEMENT, L.L.C. first disclosed a stake in CRNX in Q3 2023 at 361,904 shares (US$10.8M). The position peaked in Q2 2026 at 8,989,098 shares, worth US$336.4M. Across 12 filings, FARALLON CAPITAL MANAGEMENT, L.L.C. increased the stake 9 time(s), trimmed it 2 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 8,989,098 shares valued at US$336.4M — an increase of 651,000 shares quarter over quarter.. Notable position changes include a 9840% increase in Q2 2024, a 134% increase in Q3 2024, a 251% increase in Q4 2024.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 361.90K | $10.76M | New |
| Q4 2023 | 122.90K | $4.37M | Reduce |
| Q1 2024 | 5.00K | $234.05K | Reduce |
| Q2 2024 | 497.00K | $22.26M | Add |
| Q3 2024 | 1.16M | $59.38M | Add |
| Q4 2024 | 4.08M | $208.36M | Add |
| Q1 2025 | 4.61M | $154.45M | Add |
| Q2 2025 | 4.65M | $133.62M | Add |
| Q3 2025 | 5.77M | $240.32M | Add |
| Q4 2025 | 6.93M | $322.74M | Add |
| Q1 2026 | 8.34M | $302.84M | Add |
| Q2 2026 | 8.99M | $336.37M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About CRNX and 13F data
CRNX (CRINETICS PHARMACEUTICALS IN) is a company whose sector is not yet classified in our data. 37 other funds we track also report a position in CRNX — the largest reported positions include Farallon Capital Management (US$336.4M), DRIEHAUS CAPITAL MANAGEMENT LLC (US$241.9M), Bellevue Group AG (US$98.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding CRNX
- Farallon Capital Management 8.99M sh · $336.37M · Q2 2026
- DRIEHAUS CAPITAL MANAGEMENT LLC 6.46M sh · $241.87M · Q2 2026
- Bellevue Group AG 2.62M sh · $98.04M · Q2 2026
- BAKER BROS. ADVISORS LP 2.35M sh · $87.99M · Q2 2026
- Siren, L.L.C. 1.42M sh · $53.17M · Q2 2026
- First Light Asset Management, LLC 1.36M sh · $50.92M · Q2 2026
- Novo Holdings A/S 1.32M sh · $49.39M · Q2 2026
- ADAR1 Capital Management, LLC 1.22M sh · $45.73M · Q2 2026
- MONTANOVA CAPITAL, LLC 1.19M sh · $44.39M · Q2 2026
- ORBIMED ADVISORS LLC 999.00K sh · $37.38M · Q2 2026
More on FARALLON CAPITAL MANAGEMENT, L.L.C.
FAQ
How long has FARALLON CAPITAL MANAGEMENT, L.L.C. held CRNX?
FARALLON CAPITAL MANAGEMENT, L.L.C. has disclosed CRNX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is FARALLON CAPITAL MANAGEMENT, L.L.C.'s current position in CRNX?
As of Q2 2026, FARALLON CAPITAL MANAGEMENT, L.L.C. holds 8.99M shares of CRNX (CRINETICS PHARMACEUTICALS IN), valued at $336.37M, representing 1.56% of its reported portfolio and ranking #22.
Has FARALLON CAPITAL MANAGEMENT, L.L.C. been buying or selling CRNX?
In the latest 13F filing (Q2 2026), FARALLON CAPITAL MANAGEMENT, L.L.C. increased its position in CRNX. The position peaked in Q2 2026 at 8.99M shares.
Which other funds hold CRNX?
Other major institutional holders of CRNX include Farallon Capital Management, DRIEHAUS CAPITAL MANAGEMENT LLC, Bellevue Group AG, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.